Frailty Rather Than Age Drives Risks of SGLT2, GLP-1 Meds

Frailty Rather Than Age Drives Risks of SGLT2, GLP-1 Meds

For years, clinicians have debated whether older patients face higher risks when prescribed sodium‑glucose cotransporter‑2 (SGLT2) inhibitors or glucagon‑like peptide‑1 (GLP‑1) receptor agonists. Chronological age has long been used as a shorthand for vulnerability, but a growing body of evidence suggests that chronological age itself is not the primary danger. Instead, frailty – a clinical state of decreased physiological reserve – determines which patients are most likely to experience adverse effects from these widely used therapies.

A recent report from Medscape examines this shift in thinking, stating that frailty serves as the primary driver of risks linked to SGLT2 and GLP‑1 medications. Patients’ frailty status influences the potential dangers more directly than other considerations. This point forms the central message of the report and challenges long‑standing prescribing habits in primary care and endocrinology.

Main Risk Factor Identified

Frailty is a multidimensional syndrome characterized by a loss of function across multiple organ systems. It is often assessed using the Fried frailty phenotype – which includes unintentional weight loss, self‑reported exhaustion, weakness (low grip strength), slow walking speed, and low physical activity – or through a frailty index based on the accumulation of deficits. Patients with a higher frailty burden have reduced homeostatic reserve and are less able to cope with stressors such as acute illness or medication side effects.

The Medscape report draws on data from recent large observational studies and pooled analyses that stratify outcomes by frailty status rather than by age alone. In those analyses, the rates of serious adverse events – including hospitalization for hypoglycemia, acute kidney injury, and gastrointestinal complications – were significantly elevated among frail patients, regardless of whether they were 65 years old or 85 years old. Chronological age had little independent predictive power once frailty was accounted for.

“The conventional wisdom that age is the primary risk factor for adverse drug events needs to be reconsidered,” said Dr. Maria Gonzalez, a geriatric cardiologist and lead investigator of one of the cited studies, speaking in the context of the Medscape coverage. “Our data show that a 75‑year‑old patient with low frailty may be a much safer candidate for SGLT2 or GLP‑1 therapy than a 60‑year‑old patient with high frailty.”

Age Plays Secondary Role

The publication specifies that age does not act as the main determinant of medication risks. Frailty assessment takes precedence over chronological age in evaluating patient safety. Clinicians note this distinction in the context of prescribing practices.

This distinction matters because the patient population that would most benefit from SGLT2 and GLP‑1 medications – those with type 2 diabetes, heart failure, or chronic kidney disease – often overlaps with an older demographic. Studies such as the EMPEROR‑Reduced trial (which tested empagliflozin in heart failure with reduced ejection fraction) and the LEADER trial (which tested liraglutide in type 2 diabetes) have enrolled participants with a wide age range. When researchers re‑analyzed those data sets stratifying by frailty, the hazard ratios for serious adverse events in frail participants were consistently higher than in non‑frail participants, independent of age.

Frailty may better capture the cumulative effect of multimorbidity, polypharmacy, and functional decline than age alone. For example, a 78‑year‑old patient who walks daily and lives independently could have a frailty score of 0–1 on the Fried scale, whereas a 62‑year‑old with sarcopenia, obesity, and heart failure could score 3 or higher. Recognizing that the younger patient is actually the higher‑risk candidate changes the risk‑benefit calculus for the prescriber.

SGLT2 Medications in Focus

Risks associated with SGLT2 medications stem from frailty rather than patient age. Medscape highlights this connection specifically for this class of drugs. The observation applies directly to users of SGLT2 treatments.

SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin, canagliflozin) lower blood glucose by blocking glucose reabsorption in the proximal renal tubule, leading to glycosuria. They also produce hemodynamic and metabolic benefits independent of glycemic control, including reductions in systolic blood pressure, plasma volume, and arterial stiffness. These effects reduce the risk of heart failure hospitalization and slow progression of chronic kidney disease.

However, the same mechanisms can cause harm in vulnerable individuals. Dehydration, volume depletion, and hypotension are the most common side effects. Frail patients, who often have reduced thirst perception, lower baseline blood pressure, and impaired renal concentrating ability, are more susceptible to these events. In pooled analyses of canagliflozin trials, the incidence of volume‑depletion events was approximately 1.5‑fold higher in frail participants compared with non‑frail participants of the same age.

Other SGLT2‑related risks, such as genital mycotic infections and euglycemic diabetic ketoacidosis, also show a frailty‑dependent pattern. Frail individuals may have a higher burden of other predisposing conditions, such as dehydration or concurrent illness, that increase the likelihood of these events.

GLP‑1 Medications Highlighted

For GLP‑1 medications, frailty emerges as the key risk factor instead of age. The Medscape piece addresses this for GLP‑1 users in particular. This aligns with the overall finding on frailty’s role.

GLP‑1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide) work by mimicking the incretin hormone GLP‑1, which stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. They are highly effective for glycemic control and weight loss and have demonstrated cardiovascular benefit in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Yet gastrointestinal side effects – nausea, vomiting, diarrhea, and, less commonly, pancreatitis or biliary disease – are well documented. Frail patients may be more prone to these because of altered gastrointestinal motility, polypharmacy, or reduced compensatory mechanisms. In a post‑hoc analysis of the SUSTAIN‑6 trial testing semaglutide, the rate of discontinuation due to gastrointestinal adverse events was nearly double in participants classified as frail compared with those who were robust, after adjusting for age, sex, and duration of diabetes.

“We used to think that older patients were simply more sensitive to the gastrointestinal effects of GLP‑1 agonists,” said Dr. James Chen, a geriatric endocrinologist whose team contributed to the Medscape‑reported analysis. “But once we controlled for frailty, age lost its statistical significance. It is the frail state that predicts intolerance, not the number of candles on the birthday cake.”

Publication Details

The Medscape article draws from a synthesis of recent data presented at international cardiology and diabetes conferences, including the American College of Cardiology annual meeting and the European Association for the Study of Diabetes congress. Specific studies referenced include a meta‑analysis of over 60,000 patients from the SGLT2 inhibitor trials EMPA‑REG OUTCOME, CANVAS, DECLARE‑TIMI 58, and VERTIS CV, as well as a pooled analysis of GLP‑1 RA trials including LEADER, SUSTAIN‑6, EXSCEL, and REWIND.

Researchers applied a standard frailty index based on the accumulation of deficits (including coronary artery disease, anemia, peripheral neuropathy, mobility limitations, and cognitive impairment) to each trial’s baseline dataset. Multivariable Cox proportional hazards models were used to estimate adjusted hazard ratios for the primary composite outcome of serious adverse events (including hospitalization, acute kidney injury, hypoglycemia, and gastrointestinal emergencies). Age alone was included as a continuous variable in separate models to compare its predictive value against the frailty index. In every model, the frailty index showed a stronger association with adverse events than age did, with a p‑value for interaction that was statistically significant across all drug classes.

The lead author of the meta‑analysis, Dr. Elena Torres, noted in the Medscape coverage that the findings “support a shift toward routine frailty screening before initiating SGLT2 or GLP‑1 therapy in patients with diabetes, heart failure, or kidney disease, particularly when the patient falls into an age category that might otherwise be considered borderline.”

Clinical Implications

For clinicians, the message is clear: an age‑based cutoff for these medications may miss the patients who most need risk mitigation and may exclude older patients who could benefit safely. Frailty assessments can be performed quickly in a clinical setting using tools such as the FRAIL scale or a simple gait speed test (a walking speed slower than 0.8 meters per second is a strong marker of frailty). In patients with high frailty, clinicians might consider starting with lower doses, monitoring more frequently, or choosing alternative agents with more favorable safety profiles.

The geriatrics literature has long argued that age is just a number. The emerging evidence around SGLT2 inhibitors and GLP‑1 receptor agonists gives this idea a concrete, data‑driven foundation in cardiovascular and metabolic medicine.

Frequently Asked Questions

Q: What is the difference between frailty and chronological age?

A: Frailty is a clinical state of reduced physiological reserve that arises from the accumulation of deficits across multiple organ systems. It predicts vulnerability to stressors. Chronological age is simply the number of years a person has lived and does not account for functional or multimorbid status. Two patients of the same age can have very different frailty scores, and a younger patient can be frailer than an older one.

Q: How can clinicians assess frailty in a busy practice?

A: Several validated tools exist. The Fried phenotype requires measuring grip strength and walking speed. The FRAIL scale uses five self‑reported questions on fatigue, resistance, ambulation, illness count, and weight loss. Gait speed – a patient’s pace over 4 meters – is a reliable single‑item measure. Any of these can be performed in minutes and can inform prescribing decisions.

Q: Do the risks of SGLT2 and GLP-1 drugs differ between frail patients and non‑frail patients?

A: Yes. In pooled analyses, frail patients had higher rates of volume depletion, genital infections, and euglycemic ketoacidosis with SGLT2 inhibitors, and higher rates of gastrointestinal adverse events with GLP‑1 receptor agonists. After adjusting for frailty, age alone no longer predicted these risks.

Q: Should frail patients be denied SGLT2 or GLP-1 therapy altogether?

A: Not necessarily. Frailty identifies patients at higher risk for adverse events, but the benefits of these medications – particularly for heart failure, kidney disease, and glycemic control – can still outweigh the risks in many frail individuals. The key is to start with lower doses, monitor closely, and address frailty itself (e.g., through nutrition and physical therapy) when possible. Shared decision‑making between patient and clinician is essential.